On December 22, NonaBio, a company specializing in fully human antibody technology, and Porton Pharma Solutions, a CDMO company, officially entered into a deep strategic cooperation agreement. The two parties will focus on the full lifecycle R&D and production of novel antibody-based therapies, including bispecific and multi-antibody formulations. Through the synergy of "innovative technology platforms + industrialization capabilities," they aim to address pain points in the industry such as difficult process development, high compliance requirements, significant cost challenges, and long translation cycles, accelerating the transition of innovative therapies from the laboratory to clinical practice and the market.

In this collaboration, both parties will leverage their complementary strengths to form a joint development and management team, promoting the integrated development and full-process management of NonaBio's related projects. They will achieve deep collaboration in key areas such as project management and quality systems, focusing on the entire lifecycle of complex antibody projects (including bispecific antibodies, multispecific antibodies, and asymmetric antibodies).

At the R&D translation level, leveraging NonaBio's fully human antibody technology platform, high-affinity, low-immunogenicity, high-quality candidate antibody molecules can be rapidly generated. Building on this, and combining Porton's CMC technology expertise and large-scale production capabilities, both parties will jointly advance process development and optimization, shortening the translation cycle from preclinical to Phase I/II clinical trials.

In terms of compliance and supply assurance, Porton's quality system, audited by the EU QP, will safeguard the project and ensure that it meets the global regulatory requirements of China, the US, and Europe, thus facilitating the globalization of the product. For NonaBio's differentiated needs, customized solutions will be provided to ensure clinical supply and commercial competitiveness from core dimensions such as scale-up, cost, and quality.

NonaBio CEO Hong Di stated that this collaboration will strengthen the company's comprehensive capabilities throughout the entire lifecycle of complex antibody drugs. Leveraging Porton's expertise in CMC development, global compliance, and commercial manufacturing, the company can efficiently transform antibody discovery technologies into globally competitive clinical candidate molecules and commercial products, achieving a closed-loop value chain from "original innovation" to "global delivery."

Boteng Co., Ltd.Chairman and General Manager Ju Nianfeng stated that Porton Pharma Solutions has built a one-stop, full-category CMC technology platform and a global compliance system. The company will leverage its advantages in complex drug process development, manufacturing, and regulatory filing to accelerate the industrialization of complex antibodies and conjugate therapies.

This collaboration marks the first deep partnership between NonaBio and Porton Pharma Solutions in the field of complex antibodies. The two companies will gradually build a synergistic and efficient long-term cooperation mechanism to jointly create a benchmark model of "Chinese innovation + global manufacturing."

https://finance.eastmoney.com/a/202512223598545881.html